Objectives: In this in vitro study, we determined whether meso-tetraphenyl chlorin disulphonate (TPCS 2a )-based photochemical delivery of bleomycin was able to potentiate the cytotoxicity of bleomycin on bladder cancer cells.
Introduction
The initial treatment of non-muscle invasive bladder cancer (NMIBC) is transurethral resection, followed by intravesical therapy (i.e., chemotherapy or immunotherapy) [1] . However, intravesical therapy is not without toxicity, and a substantial percentage of treated patients still experiences tumor recurrences or progression to muscle-invasive bladder cancer. Therefore, improved treatment modalities are urgently needed.
Photodynamic therapy (PDT) is a potential treatment modality for NMIBC. PDT involves the administration of a photosensitizer and its subsequent activation by light of an appropriate wavelength. The result is the destruction of cells containing the photosensitizer. Clinical trials with PDT have shown promising results in the treatment of bladder cancer [2, 3] . Photochemical internalization (PCI) is a new technology that can be regarded as an enhanced PDT modality. PDT and PCI share many fundamental photodynamic properties, but PCI acts as a light-directed drug-delivery system by triggered release of endocytosed macromolecules into the cytosol [4, 5] . Thus, PCI can help therapeutic molecules reach their intracellular target of action, realizing their therapeutic potential, instead of being degraded by lysosomal hydrolases. The PCI effect is achieved by photosensitizing compounds specifically localizing in the membranes of endocytic vesicles, destroying these membranes by an oxidative process after illumination.
Bleomycin is used in multiple, standard cancer chemotherapy regimens, it has also been studied as intravesical treatment for NMIBC with only limited success [6, 7] . The hydrophilic and relatively large chemical structure limits the ability of bleomycin to penetrate membranous structures, but in many cell types bleomycin can be taken up by endocytosis. In this case, bleomycin accumulates in endocytic vesicles, where it may be degraded; or it can enter slowly into the cytosol, where it can be degraded by bleomycin hydrolase before reaching its therapeutic target in the nucleus. However, bleomycin cytotoxicity is highly increased when the cytosol is exposed to similar amounts of bleomycin following electroporation [8] . Thus, bleomycin may become a very efficient and specific chemotherapeutic agent when it is combined with a treatment modality that activates its therapeutic potential only in the target environment. PCI of bleomycin inhibits tumor growth in different animal tumor models in a synergistic fashion [9, 10] .
Firstly, as bladder cancer is potentially well suited for effective treatment by PCI because it is easily accessible for both intravesical instillation and illumination, we studied the relative cell-kill effect of meso-tetraphenyl chlorin disulphonate (TPCS 2a )-based PDT [11] in 4 human bladder cancer cell lines and a rat bladder cancer cell line (anticipating future animal studies). Secondly, we studied whether TPCS 2a -based photochemical delivery of bleomycin potentiated the cytotoxicity of bleomycin on these bladder cancer cell lines. Three commonly used antibladder cancer intravesical chemotherapeutic agents (i.e., epirubicin, gemcitabine, and mitomycin C) were used as controls.
Materials and methods

Cell lines and culture conditions
The human urothelial carcinoma (UC) cell lines RT4, RT112, 253J, T24 [17] , and rat UC cell line AY-27 (kindly provided by Dr. Ronald Moore, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada) were grown as a monolayer culture in RPMI-1640 medium with L-glutamine (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO), penicillin G (100 U/ml), and streptomycin (100 μg/ml) (Invitrogen) at 371C in a humidified 95% air/5% carbon dioxide atmosphere. Medium was changed twice weekly and cells were passaged using trypsin ethylenediaminetetraacetic acid (Invitrogen) when confluent. For combination therapy experiments, cells were prepared as described previously and after incubation in TPCS 2a -free culture medium for 3 hours, cells were subsequently exposed to increasing doses of epirubicin (Pfizer bv, Capelle a/d IJssel, The Netherlands) (0-48.6 mM), gemcitabine (Sun Pharmaceutical Industries Europe B.V., Hoofddorp, The Netherlands) (0-65.6 mM), mitomycin C (Kyowa Hakko Kirin Co Ltd., Tokyo, Japan) (0-65.6 mM), or bleomycin (Euro Nippon Kayaku GmbH, Frankfurt, Germany) (0-81.0 mM). All solutions were prepared on the day of use. After incubation for 1 more hour, the cells were illuminated for different periods (0-5 min) as described earlier. After illumination, cells were washed 3 times with culture medium. Cell proliferation was measured after 72 hours. Treatment doses used in these studies were selected to evaluate whether additive effects occurred and were not optimized for treatment outcome.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay
The effect of chemotherapy and PCI was determined by MTT assay. After 72 hours of treatment, 30 μl of 5 mg/ml MTT solution (Sigma-Aldrich) prepared in phosphatebuffered saline was added to the medium. Blue dye taken up by the cells after 4 hours of incubation was dissolved in dimethyl sulfoxide (100 μl per well) and optical density at 595 nm was read on an automated microplate reader (BioRad 3550, BioRad Laboratories, Hercules, CA). The bleomycin experiments were performed in quadruplicate and repeated one time by another laboratory worker; the control experiments with epirubicin, gemcitabine, and mitomycin C were performed at least once in quadruplicate.
Statistical analysis
In each combination experiment (with epirubicin, gemcitabine, mitomycin C, and bleomycin), the Wald test was used to test for statistical significance of differences in relative cell survival between the treatment groups (control, PDT alone, chemotherapy alone, and combination). P o 0.05 was considered statistically significant.
Results
Chemotherapeutic-and TPCS 2a -based PDT single treatment effects
PDT alone showed a clear phototoxic illumination timedependent inhibition of cell proliferation in all 5 cell lines (Fig. 1) . The viability of all cell lines was reduced to o40% of control with 360-second illumination. A further increase of the light dose resulted in approximately 99% cell death at 600 seconds (data not shown).
TPCS 2a pretreatment followed by chemotherapy treatment alone (without illumination) demonstrated a clear dose-dependent inhibition of cell proliferation in all 5 cell lines tested (Fig. 2) .
Chemotherapeutic-and TPCS 2a -based PDT combination effects
To evaluate the PCI therapy effect, chemotherapy was combined with TPCS 2a and light treatment (Fig. 2) . Combination of PDT and bleomycin was clearly superior to the single treatment modalities in the human T24 cell line and the rat AY-27 cell line, indicating at least an additive effect, suggesting a PCI effect. In contrast, additive treatment effects were observed for the other treatment regimens and in the other cell lines, as indicated by the parallel doseresponse curves.
The treatment effects of PDT combined with bleomycin and PDT combined with epirubicin, gemcitabine, or mitomycin C in the T24 and AY-27 cell lines are shown in Fig. 3 . To be able to compare the 4 individual chemotherapeutic agents, we selected the chemotherapeutic doses with a relative cell survival of 470%: epirubicin 5.4 mM, gemcitabine 0.8 mM, mitomycin C 65.6 mM, and bleomycin 9.0 mM for the T24 cell line and epirubicin 0.2 mM, gemcitabine 0.3 mM, mitomycin C 0.8 mM, and bleomycin 27 mM for the AY-27 cell line. As shown in Fig. 3 , PDT combined with any chemotherapeutic drug showed a significantly higher cell kill compared with PDT alone in both cell lines (P o 0.05). Similarly this combination was superior to chemotherapy alone (P o 0.05), except for epirubicin and gemcitabine treatment in the AY-27 cell line. PDT combined with bleomycin showed significantly (P o 0.001) higher cell kill than the sum of the single treatments in both cell lines, suggesting a PCI effect.
Discussion
In this in vitro study, we evaluated the therapeutic potential of TPCS 2a -based photochemical delivery of bleomycin in 4 human bladder cancer cell lines and a rat bladder cancer cell line. In the T24 and AY-27 cell lines, a significant and at least additive antiproliferative effect of the combined PDT and bleomycin treatment was observed, a clear indication of the PCI effect. For all the single treatment regimens, a clear dose-dependent inhibition of cell proliferation was observed for all 5 cell lines.
Chemotherapeutics require efficient penetration into the cytosol of the tumor cells to reach their intracellular targets and exert their therapeutic activity. The prerequisite to penetrate the plasma membrane limits the exploitable chemical structure of chemotherapeutic agents to mostly small and lipophilic compounds penetrating the plasma membrane by passive diffusion. In addition, drugs (also more hydrophilic drugs) can be taken up by means of various transporters, e.g., gemcitabine [12] .
The PDT mechanism relies on the in situ generation of cytotoxic agents by the activation of a light-sensitive drug, resulting in cell death [13] . The PCI technology is based on the same principles as PDT, i.e., the activation of a photosensitizer by light followed by formation of reactive oxygen species. Unlike PDT, the concept of PCI is based on the use of designed photosensitizers that localize preferentially in the membranes of endocytic vesicles of the targeted cells. The most efficient PCI photosensitizers have an amphiphilic structure (e.g., TPCS 2a [11] ) with a hydrophilic part inhibiting penetration through cellular membranes. The site-specific PCI-induced drug delivery adds to the welldescribed cytotoxic [13] , vascular, and immunostimulatory effects of PDT. PCI of bleomycin has already shown to induce a synergistic inhibition of tumor growth in vivo [9, 10] . Adigbli et al. [14] demonstrated an increased cytotoxic (i.e., PCI) effect of the chemotherapeutic agent, mitoxantrone, combined with the photosensitizer hypericin and illumination against multidrug-resistant bladder cancer cells. In general, PCI has the potential to reduce the systemic side effects of anticancer cytotoxic agents by reducing the drug dose required for a given effect and by conferring an increased level of treatment selectivity as the cytotoxic effect would be greatest in areas that are illuminated, decreasing systemic toxicity [15] , in line with our observations.
A prerequisite for PCI is that the molecule of interest is accumulated in endocytic vesicles at some stage in the process. We cannot preclude that our results are the consequence of off-target effects as internalization of the chemotherapeutics was not studied here. However, bleomycin is a widely used chemotherapeutic agent for several types of cancer (e.g., testicular cancers, malignant lymphomas and squamous cell carcinomas of the cervix, and head and neck cancers), with endocytosis being an important uptake mechanism [8] , probably because of its hydrophilic and relatively large chemical structure (molecular weight: 1,415.6 Da). Thus, not unexpectedly we observed the most pronounced PCI effects with bleomycin. The lower PCI effects seen for the other chemotherapeutics are most likely the consequence of their lower molecular weight and higher hydrophobicity, or their cellular uptake is dependent on the activity of transport proteins, promoting easier cytoplasmic accumulation.
Only in the T24 and AY-27 cell lines, the treatment effects of PDT combined with bleomycin were significantly higher than the sum of the single treatments. The heterogeneous response of the bladder cancer cell lines is probably a reflection of the heterogeneity of the disease. It is possible that the endocytosis and transport mechanisms of bleomycin or TPCS 2a or both differ between the various cell lines. It has been well established that the cytotoxic effect of bleomycin varies widely between different tumors as well as between different organs [16] . This might be due to differences in the cells' DNA-repair capacity, bleomycin hydrolase activity, cellular uptake mechanisms, and possibly the rate of bleomycin efflux. In our experiments, TPCS 2a represents an additional element. It is possible that different cell types use different endocytosis pathways leading to intracellular TPCS 2a accumulation resulting in cell death without endosomal release. Another possible factor for the heterogeneous antiproliferative effects are the cellular resistance mechanisms to bleomycin. A better understanding of tumor biology and pathways critical for tumor genesis may provide personalized treatment opportunities for patients with urothelial cancer.
In conclusion, TPCS 2a -based PCI of bleomycin showed a significant, at least, additive antiproliferative activity against human and rat UC cells in vitro. Therefore, PCI may have therapeutic potential as an intravesical strategy against NMIBC, provided patient stratification can be achieved based on a predictive biomarker (panel). Further studies are needed to explore whether such predictive biomarkers can be defined. Fig. 3 . TPCS 2a -based photodynamic therapy in combination with epirubicin, gemcitabine, mitomycin C, and bleomycin in the human T24 cell line and the rat AY-27 cell line. The highest chemotherapeutic doses (for chemotherapy alone) with a relative cell survival of 470% were selected, i.e., epirubicin 5.4 mM, gemcitabine 0.8 mM, mitomycin C 65.6 mM, and bleomycin 9.0 mM in the T24 cell line and epirubicin 0.2 mM, gemcitabine 0.3 mM, mitomycin C 0.8 mM, and bleomycin 27 mM in the AY-27 cell line. The chemotherapy bars represent the relative cell survival percentages after treatment with these doses. The PDT bars represent the relative cell survival percentage in the combination experiments (without chemotherapeutics) after 240-second illumination in the T24 cell line and after 120 seconds in the AY-27 cell line. These illumination times were selected because with these light doses the differences in relative cell survival are most clear. The combination therapy bars represent the relative cell survival percentages after the combination treatment with the selected chemotherapy and light doses. With these doses, any further added toxicity from the combination therapy can be detected and a comparison of the different combinations can be made. Each bar represents the percentage (mean þ SD) of viable cells from the corresponding control. * P o 0.001, compared with the sum of the single treatments. SD ¼ standard deviation.
